Physician profile
Lijo Simpson
NPI 1134106503
$4,642.23
in general payments reported to CMS, 2019-2025
48 companies · $912 in 2025
The $912 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $400 · 2020: $173 · 2021: $278 · 2022: $703 · 2023: $971 · 2024: $1,206 · 2025: $912.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,781 · Education: $308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,780.54 |
| Education | $308.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $343.13 | 2019-2025 | |
| Genentech USA, INC. | $280.13 | 2019-2025 | Phesgo, Kadcyla, Polivy |
| Seagen INC. | $266.65 | 2020-2023 | Tukysa, Padcev |
| Abbvie INC. | $258.11 | 2022-2025 | Venclexta |
| Astellas Pharma US INC | $238.83 | 2023-2025 | Padcev, Xospata, Xtandi |
| Janssen Biotech, INC. | $221.85 | 2019-2024 | Darzalex, Imbruvica, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $205.21 | 2020-2025 | Lynparza, Calquence |
| Pfizer INC. | $204.02 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $184.73 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Celgene Corporation | $158.63 | 2023-2025 | Reblozyl, Opdualag |
| Lilly USA, LLC | $147.65 | 2019-2023 | Verzenio, Jaypirca, Retevmo |
| Genzyme Corporation | $143.28 | 2021-2025 | |
| Array Biopharma INC | $139.51 | 2022-2025 | Braftovi, Mektovi, Tukysa |
| Alexion Pharmaceuticals, INC. | $130.90 | 2023-2025 | Ultomiris |
| Daiichi Sankyo INC. | $122.64 | 2020-2024 | Enhertu |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lijo Simpson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.